BioNTech will set up its Southeast Asia headquarters in Singapore. It will build a manufacturing facility in the city-state to produce its messenger RNA vaccines and other medicines to treat infectious diseases and cancer.
Southeast Asia Headquarters Singapore would be able to produce hundreds of million doses of messenger RNA vaccines each year, depending on the specific vaccine. The facility will start working as early as 2023, the German biotechnology. It would authorize the firm to increase production for Southeast Asia to address future pandemic threats.
BioNTech co-developed a vaccine for Covid-19 with U.S. drugmaker Pfizer using messenger RNA technology which makes use of genetic material to provoke an immune response against the virus. BioNTech’s expansion is supported by the Singapore Economic Development Board, a government agency under the trade ministry. The venture is required to build up to 80 additional jobs in the country.
Two shots are required with 21 days difference from each and the vaccine is 95% effective at preventing laboratory-confirmed Covid-19 illness in people without evidence of the previous infection. The vaccination against Covid-19 started countries has scrambled to secure access to enough shots to inoculate their population. Last month, the WHO said wealthy countries have received the vast majority of Covid-19 shots, while poor nations have obtained less than 1%.